U.S. News

FDA Approves Bristol-Myers's New Hepatitis Drug

From U.S. Centers for Disease Control and Prevention

March 30, 2005

On Tuesday, the Food and Drug Administration approved Bristol-Myers's Baraclude (entecavir), an oral drug for treatment of chronic hepatitis B. An FDA advisory panel, which unanimously endorsed the approval, found a potential risk of tumors was not significant enough to outweigh Baraclude's benefits. The drug was put on fast track review after regulators found it addressed a serious unmet need.

Back to other news for March 30, 2005

Adapted from:
New York Times
03.30.05; Stephanie Saul

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

Donna Summer, Coming Out, and How AIDS Changed It All: A Blog Entry by Mark S. King

Buffalo Bills Player Tweets HIV Test Results: Over-Share or Encouraging? A Blog Entry by Kellee Terrell

Study Finds HIV Infection Is an Independent Risk Factor for Lung Cancer

Broad-Spectrum Antivirals: The Future of HIV Treatment?

How Did I Get Here?

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.